CG Oncology, Inc. — Investor Relations & Filings

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapeutics for patients with urologic cancers, particularly non-muscle invasive bladder cancer (NMIBC). The company's lead product candidate is cretostimogene grenadenorepvec, an investigational, intravesically delivered oncolytic immunotherapy. This therapy is designed with a dual mechanism of action to selectively replicate within and destroy cancer cells while stimulating a systemic anti-tumor immune response. The primary goal is to provide an effective treatment that preserves the bladder and improves the quality of life for patients.